Favorable response to composite treatment including infliximab in a case of granulomatous cheilitis with Crohn's disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1346-8138|42|6|651-652

ISSN： 0385-2407

Source： THE JOURNAL OF DERMATOLOGY, Vol.42, Iss.6, 2015-06, pp. : 651-652

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 346-355

John Wiley & Sons Inc

Access to resources Recommend Favorite

Granulomatous hepatitis with hepatic mass lesions and a response to infliximab

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 7, 2015-07 ,pp. : 783-785

John Wiley & Sons Inc

Access to resources Recommend Favorite

Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease

By Geboes Karel   Rutgeerts Paul   Opdenakker Ghislain   Olson Allan   Patel Kamlesh   Wagner Carrie L.   Marano Colleen W.  

Current Medical Research and Opinion, Vol. 21, Iss. 11, 2005-11 ,pp. : 1741-1754

Informa Healthcare

Access to resources Recommend Favorite

Granulomatous slack skin disease: a new combined proton and photon therapy approach with a reported case response

By  

Journal of Radiotherapy in Practice, Vol. 14, Iss. 1, 2014-07 ,pp. : 4-9

Cambridge University Press

Access to resources Recommend Favorite

Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 5, 2015-03 ,pp. : 419-428

John Wiley & Sons Inc

Access to resources Recommend Favorite